Rationally Designed Long-Wavelength Absorbing Ru(II) Polypyridyl Complexes as Photosensitizers for Photodynamic Therapy.
Johannes KargesFranz HeinemannMarta JakubaszekFederica MaschiettoChloé SubeczMazzarine DotouRobin VinckOlivier BlacqueMickaël TharaudBruno GoudEmilio Viñuelas Zahı NosBernhard SpinglerIlaria CiofiniGilles GasserPublished in: Journal of the American Chemical Society (2020)
The utilization of photodynamic therapy (PDT) for the treatment of various types of cancer has gained increasing attention over the last decades. Despite the clinical success of approved photosensitizers (PSs), their application is sometimes limited due to poor water solubility, aggregation, photodegradation, and slow clearance from the body. To overcome these drawbacks, research efforts are devoted toward the development of metal complexes and especially Ru(II) polypyridine complexes based on their attractive photophysical and biological properties. Despite the recent research developments, the vast majority of complexes utilize blue or UV-A light to obtain a PDT effect, limiting the penetration depth inside tissues and, therefore, the possibility to treat deep-seated or large tumors. To circumvent these drawbacks, we present the first example of a DFT guided search for efficient PDT PSs with a substantial spectral red shift toward the biological spectral window. Thanks to this design, we have unveiled a Ru(II) polypyridine complex that causes phototoxicity in the very low micromolar to nanomolar range at clinically relevant 595 nm, in monolayer cells as well as in 3D multicellular tumor spheroids.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- optical coherence tomography
- induced apoptosis
- energy transfer
- gene expression
- magnetic resonance imaging
- papillary thyroid
- working memory
- cell cycle arrest
- squamous cell carcinoma
- magnetic resonance
- quality improvement
- squamous cell
- dual energy
- molecular dynamics
- combination therapy
- lymph node metastasis